ZOLADEX 10.8 mg

DRUG2 trials

Sponsors

AstraZeneca, Dr. Tamim Niazi

Conditions

Breast CancerHigh Risk Prostate Cancer

Phase 3

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

WithdrawnNCT03658213

AstraZenecaBreast Cancer

Start: 2020-03-31End: 2021-11-04Updated: 2021-05-10

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)

Not yet recruitingNCT07777263

Dr. Tamim NiaziHigh Risk Prostate Cancer

Start: 2026-10-01End: 2040-10-01Target: 600Updated: 2026-08-20